Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP-102
- Development stage
- Phase 4
- Lead developer
- CardioPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CP-102** is CardioPharma's investigational fixed-dose cardiovascular polypill comprising **atorvastatin, lisinopril, and aspirin**. The combination is intended to address cardiovascular disease through complementary mechanisms: atorvastatin competitively inhibits HMG-CoA reductase to reduce cholesterol synthesis; lisinopril inhibits angiotensin-converting enzyme to reduce angiotensin II formation and blood pressure; and aspirin irreversibly inhibits platelet cyclooxygenase to suppress thromboxane-mediated platelet aggregation. CardioPharma lists CP-102 as a pipeline line extension based on generic cardiovascular medicines, with no clinical phase or approved marketing status publicly specified. ([cardiopharma.com](https://www.cardiopharma.com/cardiapill-pipeline/))
- Other names
- atorvastatin + lisinopril + aspirinatorvastatin-lisinopril-ASA
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on CP-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP-102.